Deals In Depth: March 2013

AstraZeneca paid $240 million for rights to Moderna’s RNA therapeutics. Argon Medical acquired Angiotech’s interventional business for $362.5 million. PIPEs accounted for 31% of the $976 million in biopharma financing. FOPOs, on the other hand, dominated the $523 million in device fundraising.